- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Patent holdings for IPC class A61P 9/10
Total number of patents in this class: 8967
10-year publication summary
|
338
|
378
|
348
|
449
|
616
|
544
|
666
|
719
|
551
|
161
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1829 |
130 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
72 |
| Takeda Pharmaceutical Company Limited | 2961 |
70 |
| Shionogi & Co., Ltd. | 914 |
65 |
| Osaka University | 3143 |
63 |
| The Regents of the University of California | 18943 |
60 |
| Novartis AG | 11238 |
59 |
| AstraZeneca AB | 3042 |
54 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
50 |
| Bristol-myers Squibb Company | 5080 |
47 |
| Kowa Company, Ltd. | 1172 |
47 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
41 |
| Amarin Pharmaceuticals Ireland Limited | 267 |
40 |
| Bayer Pharma AG | 1096 |
39 |
| Astellas Pharma Inc. | 1145 |
38 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
38 |
| Mochida Pharmaceutical Co., Ltd. | 334 |
37 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
35 |
| Ono Pharmaceutical Co., Ltd. | 454 |
34 |
| Jiangsu Hengrui Medicine Co., Ltd. | 780 |
32 |
| Other owners | 7916 |